Histone Code Aberrancies in Small Cell Lung Cancer

Affiliations

¹ Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
² Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. Electronic address: rudinc@mskcc.org.

Free article

Editorial

Eric E Gardner et al. J Thorac Oncol. 2017 Apr.

Free article

. 2017 Apr;12(4):599-601.

doi: 10.1016/j.jtho.2017.02.008.

¹ Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
² Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. Electronic address: rudinc@mskcc.org.

No abstract available

Comment on

Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Augert A, Zhang Q, Bates B, Cui M, Wang X, Wildey G, Dowlati A, MacPherson D. Augert A, et al. J Thorac Oncol. 2017 Apr;12(4):704-713. doi: 10.1016/j.jtho.2016.12.011. Epub 2016 Dec 19. J Thorac Oncol. 2017. PMID: 28007623 Free PMC article.